Unknown

Dataset Information

0

Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach.


ABSTRACT: Typing of diffuse gliomas according to the WHO 2016 Classification of Tumors of the Central Nervous System is based on the integration of histology with molecular biomarkers. However, the choice of appropriate methods for molecular analysis and criteria for interpretation of test results is left to each diagnostic laboratory. In the present study, we tested the applicability of combined immunohistochemistry, direct sequencing, and multiplex ligation-dependent probe amplification (MLPA) for diagnostic assessment of IDH1/2 mutation status, chromosome 1p/19q status, and TERT promoter mutations. To this end, we analyzed a consecutive series of 165 patients with diffuse low- and high-grade gliomas (WHO grade II and III) from three Austrian centers in which tissue specimens were routinely processed. We could reliably detect IDH1/2 mutations by combining immunohistochemistry, direct sequencing, and MLPA analysis. MLPA analysis also allowed reliable detection of combined whole chromosomal arm 1p/19q codeletion when using carefully selected criteria providing an optimal balance between sensitivity and specificity. Direct sequencing proved to be suitable for identification of TERT promoter mutations, although its analytical performance remains to be assessed. To conclude, we propose a practicable combination of methods and criteria which allow reliable molecular diagnostic testing of diffuse gliomas in the real-life setting.?.

SUBMITTER: Bienkowski M 

PROVIDER: S-EPMC6102559 | biostudies-literature | 2018 Jul/Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach.

Bieńkowski Michał M   Wöhrer Adelheid A   Moser Patrizia P   Kitzwögerer Melitta M   Ricken Gerda G   Ströbel Thomas T   Hainfellner Johannes A JA  

Clinical neuropathology 20180701 4


Typing of diffuse gliomas according to the WHO 2016 Classification of Tumors of the Central Nervous System is based on the integration of histology with molecular biomarkers. However, the choice of appropriate methods for molecular analysis and criteria for interpretation of test results is left to each diagnostic laboratory. In the present study, we tested the applicability of combined immunohistochemistry, direct sequencing, and multiplex ligation-dependent probe amplification (MLPA) for diagn  ...[more]

Similar Datasets

| S-EPMC9311267 | biostudies-literature
| S-EPMC8964446 | biostudies-literature
| S-EPMC7408495 | biostudies-literature
| S-EPMC5663812 | biostudies-literature
| S-EPMC9278058 | biostudies-literature
| S-EPMC10142180 | biostudies-literature
| S-EPMC5904231 | biostudies-literature
| S-EPMC10715171 | biostudies-literature
| S-EPMC7347847 | biostudies-literature
| S-EPMC5464433 | biostudies-literature